EGFR and breast cancer: We therefore performed an open-label single-arm two step phase 2 study to investigate the potential clinical activity and safety of lapatinib in advanced breast cancer patients with HER2 non-amplified primary tumors with EGFR positive CTCs, thereby attempting to expand treatment options in patients who would not normally be considered for these therapies.